ATE416754T1 - Mukoadhäsive zusammensetzung mit polyacrylat und einem chemolockstoff - Google Patents

Mukoadhäsive zusammensetzung mit polyacrylat und einem chemolockstoff

Info

Publication number
ATE416754T1
ATE416754T1 AT04740892T AT04740892T ATE416754T1 AT E416754 T1 ATE416754 T1 AT E416754T1 AT 04740892 T AT04740892 T AT 04740892T AT 04740892 T AT04740892 T AT 04740892T AT E416754 T1 ATE416754 T1 AT E416754T1
Authority
AT
Austria
Prior art keywords
chemolockist
polyacrylate
mucoadhesive composition
composition
mucoadhesive
Prior art date
Application number
AT04740892T
Other languages
English (en)
Inventor
Pascale Hubert
Brigitte Evrard
Luc Delattre
Jacques Boniver
Philippe Delvenne
Agnes Noel
Francis Frankenne
Jean-Michel Foidart
Original Assignee
Univ Liege
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Liege filed Critical Univ Liege
Application granted granted Critical
Publication of ATE416754T1 publication Critical patent/ATE416754T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT04740892T 2003-07-31 2004-07-09 Mukoadhäsive zusammensetzung mit polyacrylat und einem chemolockstoff ATE416754T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0317999.1A GB0317999D0 (en) 2003-07-31 2003-07-31 Improvements in or relating to drug delivery systems

Publications (1)

Publication Number Publication Date
ATE416754T1 true ATE416754T1 (de) 2008-12-15

Family

ID=27799593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04740892T ATE416754T1 (de) 2003-07-31 2004-07-09 Mukoadhäsive zusammensetzung mit polyacrylat und einem chemolockstoff

Country Status (8)

Country Link
US (1) US20060228417A1 (de)
EP (1) EP1658046B1 (de)
JP (1) JP2007500673A (de)
AT (1) ATE416754T1 (de)
AU (1) AU2004262873A1 (de)
DE (1) DE602004018326D1 (de)
GB (1) GB0317999D0 (de)
WO (1) WO2005013933A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1674077A1 (de) * 2004-12-27 2006-06-28 Université de Liège Mucoadhasive Formulierungen enthaltend Chemokine
WO2006084131A2 (en) * 2005-02-01 2006-08-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Furin inhibitors and alpha-defensins for the treatment or prevention of papillomavirus infection
WO2007065128A2 (en) * 2005-11-30 2007-06-07 Auburn University Human alpha-defensins inhibit interleukin-1beta release
US7528107B2 (en) 2005-11-30 2009-05-05 Auburn University Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins
PT2347775T (pt) 2005-12-13 2020-07-14 The President And Fellows Of Harvard College Estruturas em andaime para transplante celular
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
CA2715460C (en) 2008-02-13 2020-02-18 President And Fellows Of Harvard College Continuous cell programming devices
WO2010060104A2 (en) 2008-11-24 2010-05-27 Moma Therapeutics Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone praticles as scaffolds for tissue regeneration
AU2010278702C1 (en) 2009-07-31 2016-07-14 Forsyth Dental Infirmary For Children Programming of cells for tolerogenic therapies
US11202759B2 (en) 2010-10-06 2021-12-21 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
EP2701745B1 (de) 2011-04-28 2018-07-11 President and Fellows of Harvard College Injizierbare vorgeformte makroskopische 3d-gerüste für minimal invasive verabreichung
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
JP6062426B2 (ja) 2011-06-03 2017-01-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ インサイチュー抗原生成癌ワクチン
SI2838515T1 (sl) 2012-04-16 2020-07-31 President And Fellows Of Harvard College Mezoporozni sestavki iz silicijevega dioksida za moduliranje imunskih odgovorov
CA2890757C (en) 2012-11-14 2021-10-26 Smith & Nephew, Inc. Stable thermolysin hydrogel
AU2014235578B2 (en) 2013-03-15 2017-08-17 Smith & Nephew, Inc. Dissolvable gel-forming film for delivery of active agents
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
CN109072197A (zh) 2016-02-06 2018-12-21 哈佛学院校长同事会 重塑造血巢以重建免疫
TW201808987A (zh) * 2016-06-08 2018-03-16 健生生物科技公司 Ｇｍ－ｃｓｆ變體及使用方法
US11555177B2 (en) 2016-07-13 2023-01-17 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
WO2020002650A1 (en) * 2018-06-29 2020-01-02 Targovax Asa A formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
CA2271843A1 (en) * 1996-11-14 1998-05-22 Lipomedica Ehf. Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders

Also Published As

Publication number Publication date
GB0317999D0 (en) 2003-09-03
EP1658046B1 (de) 2008-12-10
WO2005013933A1 (en) 2005-02-17
US20060228417A1 (en) 2006-10-12
DE602004018326D1 (de) 2009-01-22
EP1658046A1 (de) 2006-05-24
JP2007500673A (ja) 2007-01-18
AU2004262873A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
ATE416754T1 (de) Mukoadhäsive zusammensetzung mit polyacrylat und einem chemolockstoff
BRPI0312331A2 (pt) composições de ácido hialurônico e métodos de emprego.
DE60335560D1 (de) Zusammensetzungen enthaltend zitronensäure zur behandlung von nagelpilzerkrankungen
DE60135029D1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
HUP0300299A2 (hu) Szabad aminosavakat tartalmazó kompozíció
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BRPI0413449A (pt) compostos de quinoxalina
IL229124A0 (en) Inhibitors with a mutant form of kit
ATE423122T1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
ATE346614T1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
PA8638201A1 (es) Forma cristalina alfa del ranelato de estroncio procedimiento para su preparacion y composiciones farmaceuticas que la contienen
NO20052839L (no) NADH/NADPH-inneholdende sammensetning
AP1795A (en) Peptide deformylase inhibitors.
IS6654A (is) Stöðugt gabapentín með pH innan stýrðra marka
HUP0302441A2 (hu) Antibiotikus hatású gyógyászati készítmények
ATE536886T1 (de) Stabilisierte feste zusammensetzungen von modifizierter faktor vii
DE60323865D1 (de) Beschichtungszusammensetzung enthaltend säurefunktionelle acrylpolymere und silica
WO2004024077A3 (en) Novel composition and methods for the treatment of psoriasis
BR0009469A (pt) Tablete perfumado de detergente
FR2857593B1 (fr) Composition pharmaceutique orodispersible d'un compose antithrombotique
ITMI20030882A1 (it) Metodo per inibire l'acidificazione biologica di acque in contatto con materiali contenenti zolfo
DE50306263D1 (de) Detektion von toxischen algen
DE50302552D1 (de) Verwendung von treosulfan und derivaten davon zur behandlung der multiplen sklerose
FR2851469B1 (fr) Composition et procede de soin contenant un inhibiteur de glucosidase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties